Kardigan
- Market cap
- 1.29B
- P/E (TTM)i
- -4.48
- P/Bi
- 2.10
- EPSi
- -2.19
- Div yieldi
- 0.00%
- 52W posi
- 11%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Kardigan (KARD) | 1.29B | -4.48 | 2.10 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 128.16B | 29.45 | 6.33 | 0.00% |
| Moderna (MRNA) | 78.44B | -24.62 | 11.60 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 76.40B | 18.36 | 2.41 | 0.49% |
| argenx SE (ARGX) | 58.39B | 35.37 | 6.94 | 0.00% |
| Revolution Medicines (RVMD) | 43.05B | -22.65 | 16.52 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 71.3% below Morningstar's fair value estimate.
Fair value
Kardigan Inc earns a 5-star quantitative star rating, reflecting our opinion that this share class offers a compelling opportunity for investors. The stock currently trades at a 43% discount to our quantitative fair value estimate of $23.69 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The firm's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 2.2 falls in the bottom 20% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be cheap.
Alternatively, the company's unfavorable dividend structure is potentially concerning. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, lies in the bottom 30% compared with global peers. This could imply a planned dividend cut or relatively high share price, which, despite our favorable price/fair value ratio, is a negative attribute.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none.
By Quantitative Equity Report
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.